Annual Results Results Snapshot
Figures in Cr
Consolidate Annual Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Mar'19
Net Sales
6,672.08
6,228.63
5,652.62
5,305.79
5,393.13
4,605.75
3,934.68
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
6,672.08
6,228.63
5,652.62
5,305.79
5,393.13
4,605.75
3,934.68
Raw Material Cost
1,672.17
1,403.01
1,250.08
1,129.11
1,185.35
979.05
850.04
Purchase of Finished goods
410.96
454.91
380.09
360.50
265.92
270.93
234.93
(Increase) / Decrease In Stocks
-289.77
-142.84
78.65
-43.19
-193.93
-210.59
-92.27
Employee Cost
1,562.34
1,446.29
1,169.13
1,133.00
1,051.17
906.44
746.69
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Expenses
2,308.14
2,133.90
2,066.30
1,852.21
1,604.34
1,436.91
1,321.71
Total Expenditure (Excl Depreciation)
5,663.84
5,295.27
4,944.25
4,431.63
3,912.85
3,382.74
3,061.10
Operating Profit (PBDIT) excl Other Income
1,008.24
933.36
708.37
874.16
1,480.28
1,223.01
873.58
Other Income
42.55
28.31
2.74
50.46
87.29
4.94
9.38
Operating Profit (PBDIT)
1,050.79
961.67
711.11
924.62
1,567.57
1,227.95
882.96
Interest
78.77
56.19
50.17
17.73
16.02
27.16
18.41
Exceptional Items
12.87
0.00
0.00
0.00
0.00
-43.64
0.00
Gross Profit (PBDT)
984.89
905.48
660.94
906.89
1,551.55
1,157.15
864.55
Depreciation
278.58
272.67
275.43
286.78
183.47
157.32
115.23
Profit Before Tax
706.31
632.81
385.51
620.11
1,368.08
999.83
749.32
Tax
125.17
16.01
12.60
104.46
253.32
199.18
156.75
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
581.14
616.80
372.91
515.65
1,114.76
800.65
592.57
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
581.14
616.80
372.91
515.65
1,114.76
800.65
592.57
Share in Profit of Associates
0.87
-0.98
-30.92
5.28
31.74
0.05
-9.28
Minority Interest
1.41
0.00
0.00
24.75
31.61
28.12
1.08
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
583.42
615.82
341.99
545.68
1,178.11
828.82
584.37
Equity Capital
39.31
39.31
39.31
39.31
39.31
37.70
37.70
Face Value
2.0
2.0
2.0
2.0
2.0
2.0
2.0
Reserves
5,151.63
4,778.89
4,331.16
5,198.23
5,088.30
3,181.71
2,681.12
Earnings per share (EPS)
29.68
31.33
17.4
27.76
59.94
43.97
31.0
Diluted Earnings per share
29.68
31.33
17.4
27.76
60.81
43.97
31.0
Operating Profit Margin (Excl OI)
15.11%
14.98%
12.53%
16.48%
27.45%
26.55%
22.2%
Gross Profit Margin
14.76%
14.54%
11.69%
17.09%
28.77%
25.12%
21.97%
PAT Margin
8.72%
9.89%
6.05%
9.72%
20.67%
17.38%
15.06%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2025 is 7.12% vs 10.19% in Mar 2024
Consolidate Net Profit
YoY Growth in year ended Mar 2025 is -5.26% vs 80.07% in Mar 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2025 is 8.02% vs 31.76% in Mar 2024
Interest
YoY Growth in year ended Mar 2025 is 40.19% vs 12.00% in Mar 2024
Operating Profit Margin (Excl OI)
YoY Growth in year ended Mar 2025 has improved from Mar 2024
Compare Annual Results Of Alembic Pharma With
Figures in Cr
Consolidate Annual Results
Change(INR)
Change(%)
Net Sales
6,672.08
1,694.57
4,977.51
293.73%
Other Operating Income
0.00
0.00
0.00
Total Operating income
6,672.08
1,694.57
4,977.51
293.73%
Raw Material Cost
1,672.17
460.80
1,211.37
262.88%
Purchase of Finished goods
410.96
0.00
410.96
(Increase) / Decrease In Stocks
-289.77
4.97
-294.74
-5,930.38%
Employee Cost
1,562.34
549.12
1,013.22
184.52%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
-0.01
0.01
100.00%
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
2,308.14
274.03
2,034.11
742.29%
Total Expenditure (Excl Depreciation)
5,663.84
1,288.91
4,374.93
339.43%
Operating Profit (PBDIT) excl Other Income
1,008.24
405.66
602.58
148.54%
Other Income
42.55
36.78
5.77
15.69%
Operating Profit (PBDIT)
1,050.79
442.44
608.35
137.50%
Interest
78.77
76.16
2.61
3.43%
Exceptional Items
12.87
0.00
12.87
Gross Profit (PBDT)
984.89
366.28
618.61
168.89%
Depreciation
278.58
138.57
140.01
101.04%
Profit Before Tax
706.31
227.70
478.61
210.19%
Tax
125.17
57.57
67.60
117.42%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
581.14
170.13
411.01
241.59%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
581.14
170.13
411.01
241.59%
Share in Profit of Associates
0.87
0.00
0.87
Minority Interest
1.41
0.00
1.41
Other related items
0.00
0.00
0.00
Consolidated Net Profit
583.42
170.13
413.29
242.93%
Equity Capital
39.31
20.84
18.47
88.63%
Face Value
2.00
1.00
0.00
Reserves
5,151.63
2,107.51
3,044.12
144.44%
Earnings per share (EPS)
29.68
8.16
21.52
263.73%
Diluted Earnings per share
29.68
8.61
21.07
244.72%
Operating Profit Margin (Excl OI)
15.11%
23.94%
0.00
-8.83%
Gross Profit Margin
14.76%
21.61%
0.00
-6.85%
PAT Margin
8.72%
10.04%
0.00
-1.32%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Annual - Net Sales
Net Sales 6,672.08 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 7.12% vs 10.19% in Mar 2024
Annual - Consolidate Net Profit
Consolidate Net Profit 583.42 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -5.26% vs 80.07% in Mar 2024
Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 1,008.24 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 8.02% vs 31.76% in Mar 2024
Annual - Interest
Interest 78.77 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 40.19% vs 12.00% in Mar 2024
Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 15.11%
in Mar 2025Figures in %
YoY Growth in year ended Mar 2025 has improved from Mar 2024
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
